National Cancer Institute; Notice of Closed Meetings, 64242 [2022-23068]

Download as PDF 64242 Federal Register / Vol. 87, No. 204 / Monday, October 24, 2022 / Notices lotter on DSK11XQN23PROD with NOTICES1 Contact Person: Megan Lynne Goodall, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892, (301) 594–8334, megan.goodall@ nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Small Business: Drug Discovery and Development. Date: November 21–22, 2022. Time: 10:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Sergei Ruvinov, Ph.D., Scientific Review Officer, Center for Scientific Review, National Institutes of Health, 6701 Rockledge Drive, Room 4158, MSC 7806, Bethesda, MD 20892, 301–435– 1180, ruvinser@csr.nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Biology of the Eye. Date: November 21, 2022. Time: 11:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Jimok Kim, Ph.D., Scientific Review Officer, Center for Scientific Review, 6107 Rockledge Drive, Bethesda, MD 20892, (301) 402–8559, jimok.kim@nih.gov. Name of Committee: Center for Scientific Review Special Emphasis Panel; Member Conflict: Cell Biology, Biochemistry, and Aging. Date: November 21, 2022. Time: 12:00 p.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Rockledge II, 6701 Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Kevin Czaplinski, Ph.D., Scientific Review Officer, Center for Scientific Review, 6901 Rockledge Drive, Bethesda, MD 20892, (301) 480–9139, czaplinskik2@csr.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.306, Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 93.337, 93.393–93.396, 93.837–93.844, 93.846–93.878, 93.892, 93.893, National Institutes of Health, HHS) Dated: October 19, 2022. David W. Freeman, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–23066 Filed 10–21–22; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 17:07 Oct 21, 2022 Jkt 259001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; Early Detection Research Network: Clinical Validation Centers (U01) and Biomarker Characterization Centers (U2C). Date: November 16, 2022. Time: 9:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W260, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Robert F. Gahl, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9606 Medical Center Drive, Room 7W260, Rockville, Maryland 20850, 240–276–7869, robert.gahl@ nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; A data resource for blood and marrow transplants and adoptive cellular therapy research. Date: November 17, 2022. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W602, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Delia Tang, M.D., Scientific Review Officer, Resources Training and Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W602, Rockville, Maryland 20850, 240–276–6456, tangd@mail.nih.gov. Name of Committee: National Cancer Institute Initial Review Group; Cancer Centers Study Section (A). Date: December 1–2, 2022. Time: 10:30 a.m. to 2:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 7W530, Rockville, Maryland 20850 (Telephone Conference Call). Contact Person: Shamala K. Srinivas, Ph.D., Associate Director, Office of Referral, Review, and Program Coordination, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W530, Rockville, Maryland 20850, 240–276–6442, ss537t@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: October 19, 2022. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2022–23068 Filed 10–21–22; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Submission for OMB Review; Comment Request Periodically, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish a summary of information collection requests under Office of Management and Budget (OMB) review, in compliance with the Paperwork Reduction Act (44 U.S.C. chapter 35). To request a copy of these documents, email or call the SAMHSA Reports Clearance Officer at carlos.graham@samhsa.hhs.gov or (240) 276–0361. Proposed Project: Program Evaluation for Prevention Contract (PEPC)— Strategic Prevention Framework for Prescription Drugs (SPF-Rx) Evaluation (OMB No. 0930–0377)—Revision The Substance Abuse and Mental Health Services Administration’s (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ) aims to complete a cross-site evaluation of SAMHSA’s Strategic Prevention Framework for Prescription Drugs (SPFRx). SPF-Rx is designed to address nonmedical use of prescription drugs as well as opioid overdoses by raising awareness about the dangers of sharing medications and by working with pharmaceutical and medical communities on the risks of overprescribing. The SPF-Rx program aims to promote collaboration between E:\FR\FM\24OCN1.SGM 24OCN1

Agencies

[Federal Register Volume 87, Number 204 (Monday, October 24, 2022)]
[Notices]
[Page 64242]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-23068]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; Early Detection Research Network: Clinical Validation Centers 
(U01) and Biomarker Characterization Centers (U2C).
    Date: November 16, 2022.
    Time: 9:00 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W260, Rockville, Maryland 20850 (Telephone 
Conference Call).
    Contact Person: Robert F. Gahl, Ph.D., Scientific Review 
Officer, Special Review Branch, Division of Extramural Activities, 
National Cancer Institute, NIH, 9606 Medical Center Drive, Room 
7W260, Rockville, Maryland 20850, 240-276-7869, [email protected].

    Name of Committee: National Cancer Institute Special Emphasis 
Panel; A data resource for blood and marrow transplants and adoptive 
cellular therapy research.
    Date: November 17, 2022.
    Time: 1:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W602, Rockville, Maryland 20850 (Telephone 
Conference Call).
    Contact Person: Delia Tang, M.D., Scientific Review Officer, 
Resources Training and Review Branch, Division of Extramural 
Activities, National Cancer Institute, NIH, 9609 Medical Center 
Drive, Room 7W602, Rockville, Maryland 20850, 240-276-6456, 
[email protected].

    Name of Committee: National Cancer Institute Initial Review 
Group; Cancer Centers Study Section (A).
    Date: December 1-2, 2022.
    Time: 10:30 a.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Cancer Institute at Shady Grove, 9609 Medical 
Center Drive, Room 7W530, Rockville, Maryland 20850 (Telephone 
Conference Call).
    Contact Person: Shamala K. Srinivas, Ph.D., Associate Director, 
Office of Referral, Review, and Program Coordination, Division of 
Extramural Activities, National Cancer Institute, NIH, 9609 Medical 
Center Drive, Room 7W530, Rockville, Maryland 20850, 240-276-6442, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: October 19, 2022.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-23068 Filed 10-21-22; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.